infectious-diseases

Documents about infectious-diseases

• Optimizing telework in an epidemic context: contrasting the infectious and non-communicable diseases perspectives#223950bioRxiv / medRxiv
• ADRN Barrier/Immunoprofiling Exploratory Pilot Study#230454ClinicalTrials.gov
• Inducing Remission in Type 1 Diabetes With Alefacept#238256ClinicalTrials.gov
• Coupling time-aware SNP thresholds with genetic markers to define bacterial transmission chains in hospital surveillance#241510bioRxiv / medRxiv
• Probiotics Reduce Group B Streptococcus (GBS) Colonization During Pregnancy: A Systematic Review and Meta-Analysis#243530bioRxiv / medRxiv
• Clinical Features and Outcomes of Neuroleptospirosis in French Guiana: Insights from a Retrospective Study (2015-2021)#249472bioRxiv / medRxiv
• WHO foodborne disease estimates 2000-21: bridging the burdens of infectious and non-communicable diseases.#289170PubMed
• Antigenic seniority and convergent haemagglutinin evolution shaped the immune landscape preceding influenza B/Yamagata's extinction#298249bioRxiv / medRxiv
• Health and economic burdens of emerging infectious diseases in the USA, US territories and globally.#309087NCBI PubMed Central
• Long-Term Effects of HIV Exposure and Infection in Children#329574ClinicalTrials.gov
• Expectation, Motivation and Experience of HIV-patients Regarding Participation to an HIV Cure-related Clinical Trial#329584ClinicalTrials.gov
• Clearance of asymptomatic genital HPV infections in young adult women is shaped by host immune response#337068bioRxiv / medRxiv
• Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"#346954ClinicalTrials.gov
• Real-time forecasting of measles transmission in Mexican states hosting FIFA World Cup venues, 2026#369725bioRxiv / medRxiv
• Tolerance by Engaging Antigen During Cellular Homeostasis#407825ClinicalTrials.gov
• Gendered socioeconomic impacts of emerging infectious diseases: Insights from a mixed-methods study in Guinea.#415627NCBI PubMed Central
• Editorial: Integrated genomic and systems approaches to unravel host-virus interactions in viral infectious diseases.#418361NCBI PubMed Central
• Health-economic burden of chikungunya infection and potential cost-effectiveness of preventive vaccination in 31 countries#419968bioRxiv / medRxiv
• Diseases Have No Eyes#426908DOAB PROD Instance
• Blood and Plasma Collection For Use in Future Clinical Trials#429635ClinicalTrials.gov
• Safety and Efficacy of Sanaria's PfSPZ-CVac in Malian Adults#474817ClinicalTrials.gov
• Chemoattractant concentration–dependent tuning of ERK signaling dynamics in migrating neutrophils#491808eScholarship
• Sequence analysis of the potato aphid Macrosiphum euphorbiae transcriptome identified two new viruses#609442eScholarship
• Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals#612227eScholarship
• Epidemiology of Aspergillosis Diagnoses in US Adults Using a National EHR Database, 2013–2023#612260eScholarship
• A cluster randomised trial of cloth masks compared with medical masks in healthcare workers#201389UNSWorks Repository
• Presence of Dolosigranulum pigrum in the nasopharynx and its relationship with respiratory health status in paediatric population#10172bioRxiv / medRxiv
• Spatio-temporal transmissibility and dispersion of SARS-CoV-2 variants and sub-variants of concern in England#10217bioRxiv / medRxiv
• Mucosal IgA to pre-fusion F protein predicts protection from RSV infection in a high burden setting#10227bioRxiv / medRxiv
• Neuroinvasive Human Parvovirus 4 is associated with increased mortality in children: a multiyear retrospective observational study#18861bioRxiv / medRxiv
• Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes#123638ClinicalTrials.gov
• Anti-granulocyte macrophage colony-stimulating factor autoantibodies: A rising cause of infectious diseases#130458Unpaywall
• Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea#136382ClinicalTrials.gov
• WGS-Enabled Surveillance Improves Detection Of Transmission Events Within A Large Tertiary Care Hospital Trust In London#138705bioRxiv / medRxiv
• Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark)#148589ClinicalTrials.gov
• The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"#154708ClinicalTrials.gov
• Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women#154715ClinicalTrials.gov
• Seroprevalence of chikungunya virus in Colombo, Sri Lanka before the 2025 outbreak and implications for population susceptibility#154928bioRxiv / medRxiv
• Gametocyte production and infectivity among Ugandan malaria patients infected with P. falciparum with partial resistance to artemisinins#172250bioRxiv / medRxiv
• A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines#172374ClinicalTrials.gov
• DNA capture and amplicon enrichment approaches for next-generation sequencing of Mycoplasma genitalium directly from clinical samples#241509bioRxiv / medRxiv
• Individualized Mechanistic Modeling Reveals Viral Infectivity and CD8+ T cell Expansion as Drivers of Heterogeneous Influenza Dynamics#243508bioRxiv / medRxiv
• The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys#256954ClinicalTrials.gov
• Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection#261182bioRxiv / medRxiv
• Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children#290853ClinicalTrials.gov
• Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori#291000ClinicalTrials.gov
• Novel ATF6 luminal domain variant in Achromatopsia#307751Figshare
• Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients#356537ClinicalTrials.gov
• Disentangling Confounders from Pathology in Long-COVID Trajectory Prediction for Women: An Interpretable Large-Language-Model Approach#359685bioRxiv / medRxiv
• ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19#366653ClinicalTrials.gov